FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap
November 17, 2026


The FDA has rejected Summit Therapeutics’ ivonescimab lung cancer treatment, a PD-1xVEGF bispecific antibody, in a complete response letter sent to the companies. Summit announced the decision on Sunday, 15 November 2026.
Why the FDA rejected the ivonescimab lung cancer application
The application covered ivonescimab given with platinum-containing chemotherapy for locally advanced or metastatic non-small cell lung cancer in patients who had already received an EGFR tyrosine kinase inhibitor. The FDA concluded that substantial evidence of effectiveness is not established without a statistically significant overall survival improvement.
FDA reviewers said the drug slowed lung cancer worsening, but the absence of a survival benefit “does not support the positive benefit-risk profile in support of approval”. Summit says the letter means the application cannot be approved in its present form.
The HARMONi trial evidence
The application rests on the global HARMONi study, a randomised, double-blind Phase III trial in patients with EGFR-mutated disease who had previously been treated with a third-generation EGFR inhibitor. Summit says HARMONi met its progression-free survival primary endpoint.
The primary overall survival analysis showed a positive trend that did not reach statistical significance. In a post hoc analysis with longer follow-up of Western patients, Summit reports a consistent overall survival benefit, with a hazard ratio of 0.76 across the full population.
Where ivonescimab is already available
Ivonescimab is approved only in China. China’s National Medical Products Administration approved it on 25 April 2025 for first-line treatment of PD-L1-positive non-small cell lung cancer. Syenza News covered that approval in an earlier article. The approval was based on the HARMONi-2 trial, which compared ivonescimab with pembrolizumab (Keytruda), and Syenza News has reported those results separately.
Akeso has made the drug available in China since 2024 for this indication, and Summit’s US application was the first attempt to bring it to the American market. Syenza News has also followed the drug’s clinical data and partnering, including the collaboration with Pfizer.
What the rejection means for the class
BioSpace reports that ivonescimab would have been the first approval for a PD-1xVEGF bispecific antibody in the US. Summit’s co-chief executive, Robert Duggan, said the company was disappointed for patients awaiting more treatment options in this setting.
What to watch
The letter does not say whether Summit will resubmit or add a survival analysis, and the material reviewed for this article does not settle that question. Any next step will depend on how the overall survival data mature, which is the point the FDA has put at the centre of its decision.
Source: Summit Therapeutics, update regarding the ivonescimab Biologics License Application, 15 November 2026; BioSpace, 15 November 2026; STAT News, 15 November 2026.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.




